Morepen Laboratories Ltd
Morepen Laboratories Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Based on Morepen Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue: Rs. Q2 FY27 Financials (Page 3): - Revenue: Rs.
From Morepen Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 revenue: Rs. 755 Cr (Page 3)
- Q2 FY27 EBITDA: Rs. 132 Cr, +273% YoY (Page 3)
- Q2 FY27 EBITDA margin: 17.45%, +897 bps YoY (Page 3)
- Q2 FY27 PAT: Rs. 89 Cr, +117% YoY (Page 3)
- H1 FY27 revenue: Rs. 1330 Cr, +57% YoY (Page 4)
- H1 FY27 EBITDA: Rs. 220 Cr, +177% YoY (Page 4)
- H1 FY27 EBITDA margin: 16.5%, +894 bps YoY (Page 4)
- H1 FY27 PAT: Rs. 145 Cr, +243% YoY (Page 4)
- Q2 CDMO revenue: Rs. 253 Cr, +52% QoQ (Page 6)
- Q2 CDMO share of API + CDMO revenue: 52% (Page 6)
- H1 export revenue: Rs. 654 Cr, +122% YoY, exports now ~50% of sales (Page 8)
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Manufacturing Capacity Expansion:
- API + CDMO capacity increased from 614 KL and planned to expand to 800 KL, with further expansion behind visibility (Page 9).
- CDMO capacity commissioned ahead of schedule, currently at 614 KL (Page 11).
- Innovation Hub & New Technologies:
- Innovation Hub development mentioned as part of scale & capability enhancement (Page 14).
2 more points from Morepen Laboratories Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q2 FY27 results?
Q2 FY27 revenue: Rs. Q2 FY27 Financials (Page 3): - Revenue: Rs.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 58.6 with a market cap of ₹6,885 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Manufacturing Capacity Expansion: - API + CDMO capacity increased from 614 KL and planned to expand to 800 KL, with further expansion behind visibility (Page 9). - CDMO capacity commissioned ahead of schedule, currently at 614 KL (Page 11). - Innovation Hub & New Technologies: - Innovation Hub development mentioned as part of scale & capability enhancement (Page 14). - The Commercial CDMO scale-up is ongoing and described as driving growth with Q2 CDMO revenue reaching Rs.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.